Fampridine-SR

DRUG7 trials

Sponsors

Acorda Therapeutics, University of Southern Denmark

Conditions

Multiple SclerosisMuscle SpasticitySpinal Cord Injury

Phase 3

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

CompletedNCT00041717

Acorda TherapeuticsMuscle Spasticity, Spinal Cord Injury

Start: 2002-07-31End: 2004-05-31Updated: 2020-01-14

Study of Oral Fampridine-SR in Multiple Sclerosis

CompletedNCT00127530

Acorda TherapeuticsMultiple Sclerosis

Start: 2005-05-31End: 2006-09-30Updated: 2018-09-11

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

CompletedNCT00483652

Acorda TherapeuticsMultiple Sclerosis

Start: 2007-05-31End: 2008-05-31Updated: 2016-02-04

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

CompletedNCT00649792

Acorda TherapeuticsMultiple Sclerosis

Start: 2007-08-31End: 2011-04-30Updated: 2012-02-28

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

CompletedNCT00648908

Acorda TherapeuticsMultiple Sclerosis

Start: 2006-06-30End: 2011-04-30Updated: 2012-02-27

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

CompletedNCT01683838

Acorda TherapeuticsMuscle Spasticity, Spinal Cord Injury

Start: 2002-06-30End: 2004-02-29Updated: 2017-08-25

Phase 4

FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra

CompletedNCT01656148

University of Southern DenmarkMultiple Sclerosis

Start: 2012-06-30End: 2014-05-31Updated: 2018-08-23

Related Papers

4-Aminopyridine treatment for nerve injury resulting from radical retro-pubic prostatectomy: a single-center double-blind, randomized, placebo-controlled study

Trials2024-05-211 citations

Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.

2016-09-1426 citations

Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment

Multiple Sclerosis Journal2014-05-2254 citations

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

2009-02-01368 citations